The Accu-Chek® SmartGuide CGM solution provides 14 days of accurate1 real-time glucose values for adults living with type 1 and type 2 diabetes on flexible insulin therapy.The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur.The solution is set to launch in selected European markets in the coming months. Basel, 09 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received t ...